Survival of many altricial animals critically depends on the sense of smell. Curiously, the olfactory system is rather immature at birth and undergoes a maturation process, which is poorly understood. Using patch-clamp technique on mouse olfactory sensory neurons (OSNs) with a defined odorant receptor, we demonstrate that OSNs exhibit functional maturation during the first month of postnatal life by developing faster response kinetics, higher sensitivity, and most intriguingly, higher selectivity. OSNs expressing mouse odorant receptor 23 (MOR23) are relatively broadly tuned in neonates and become selective detectors for the cognate odorant within 2 weeks. Remarkably, these changes are prevented by genetic ablation of olfactory marker protein (OMP), which is exclusively expressed in mature OSNs. Biochemical and pharmacological evidence suggests that alteration in odorant-induced phosphorylation of signaling proteins underlie some of the OMP Ϫ/Ϫ phenotypes. Furthermore, in a novel behavioral assay in which the mouse pups are given a choice between the biological mother and another unfamiliar lactating female, wild-type pups prefer the biological mother, while OMP knock-out pups fail to show preference. These results reveal that OSNs undergo an OMP-dependent functional maturation process that coincides with early development of the smell function, which is essential for pups to form preference for their mother.

BACKGROUND: Clinical trials of radiation after radical cystectomy (RC) and chemotherapy for bladder cancer are in development, but inclusion and stratification factors have not been clearly established. In this study, the authors evaluated and refined a published risk stratification for locoregional failure (LF) by applying it to a multicenter patient cohort. METHODS: The original stratification, which was developed using a single-institution series, produced 3 subgroups with significantly different LF risk based on pathologic tumor (pT) classification and the number of lymph nodes identified. This model was then applied to patients in Southwest Oncology Group (SWOG) 8710, a randomized trial of RC with or without chemotherapy. LF was defined as any pelvic failure before or within 3 months of distant failure. RESULTS: Patients in the development cohort and the SWOG cohort had significantly different baseline characteristics. The original risk model was not fully validated in the SWOG cohort, because lymph node yield was not as strongly associated with LF as in the development cohort. Regression analysis indicated that margin status could improve the model. A revised stratification using pT classification, margin status, and the number of lymph nodes identified produced 3 subgroups with significantly different LF risk in both cohorts: low risk (pT2), intermediate risk (pT3 with negative margins AND 10 lymph nodes identified), and high risk (pT3 with positive margins OR <10 lymph nodes identified) with 5-year LF rates of 8%, 20%, and 41%, respectively, in the SWOG cohort and 8%, 19%, and 41%, respectively, in the development cohort. CONCLUSIONS: A model incorporating pT classification, margin status, and the number of lymph nodes identified stratified LF risk in 2 different RC populations and may inform the design of future trials. Cancer 2014;120:1272-80. V C 2014 American Cancer Society.KEYWORDS: bladder cancer, urothelial cancer, local failure, adjuvant radiation. INTRODUCTIONPatients with muscle-invasive bladder cancer who undergo radical cystectomy plus bilateral pelvic lymphadenopathy (RC) with or without the receipt of perioperative chemotherapy have an estimated 5-year overall survival rate of approximately 50%.1 Although considerable attention has been given to the problem of distant relapse after RC, approximately 33% of patients with pT3 tumors develop a recurrence within the pelvis, either as isolated locoregional failures (LF) or cosynchronous with distant metastases.2 Several organizations are now considering clinical trials to assess the impact of radiation therapy (RT) after RC. However, criteria for the selection and stratification of patients most likely to benefit from adjuvant RT in these trials have not been clearly defined. A LF risk-stratification model derived from a single-institution experience has recently been published but not externally validated. 3 The purpose of this study was to assess the validity of this LF stratification model within the Southwest Oncology Group (SWOG) 8710 datab...

Summary In many sensory organs, specialized receptors are strategically arranged to enhance detection sensitivity and acuity. It is unclear whether the olfactory system utilizes a similar organizational scheme to facilitate odor detection. Curiously, olfactory sensory neurons (OSNs) in the mouse nose are differentially stimulated depending on the cell location. We therefore asked whether OSNs in different locations evolve unique structural and/or functional features to optimize odor detection and discrimination. Using immunohistochemistry, computational fluid dynamics modeling, and patch clamp recording, we discovered that OSNs situated in highly stimulated regions have much longer cilia and are more sensitive to odorants than those in weakly stimulated regions. Surprisingly, reduction in neuronal excitability or ablation of the olfactory G protein in OSNs does not alter the cilia length pattern, indicating that neither spontaneous nor odor-evoked activity is required for its establishment. Furthermore, the pattern is evident at birth, maintained into adulthood, and restored following pharmacologically induced degeneration of the olfactory epithelium, suggesting that it is intrinsically programmed. Intriguingly, type III adenylyl cyclase (ACIII), a key protein in olfactory signal transduction and ubiquitous marker for primary cilia, exhibits location-dependent gene expression levels, and genetic ablation of ACIII dramatically alters the cilia pattern. These findings reveal an intrinsically programmed configuration in the nose to ensure high sensitivity to odors.

No abstract

No abstract